About Sai Phytoceuticals
Sai Phytoceuticals is a company based in New Delhi (India) founded in 2002. It operates as a B2B. The company has 34 employees. Sai Phytoceuticals offers products and services including PACLITAXEL, CABAZITAXEL, CARFILZOMIB, ETOPOSIDE, and DEHYDROEPIANDROSTERONE.
- Headquarter New Delhi, India
- Employees 34
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website saiphyto.com
- Legal Name Sai Phytoceuticals Private Limited
- Date of Incorporation 23 Jun, 1995
- Jurisdiction New Delhi, Delhi, India
- Annual Revenue₹15.55 Cr
FY 2025 · +73% YoY
- Net Profit₹39.9 Lakh
FY 2025 · 3% margin
- EBITDA₹1.62 Cr
FY 2025 · 10% margin
- Employee Count34
Associated legal entities of Sai Phytoceuticals
Sai Phytoceuticals operates through Sai Phytoceuticals Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Sai Phytoceuticals Private Limited CIN U51909DL1995PTC070148 | Active | 23 Jun 1995 | New Delhi, Delhi | ₹15.5 Cr | 34 | 2 | View details |
Products & Services of Sai Phytoceuticals
Sai Phytoceuticals offers a comprehensive portfolio of products and services, including PACLITAXEL, CABAZITAXEL, CARFILZOMIB, ETOPOSIDE, and DEHYDROEPIANDROSTERONE.
Anti-cancer drug used in chemotherapy for treating various cancers.
Medication for advanced prostate cancer in pharmaceutical treatments.
Proteasome inhibitor for multiple myeloma cancer therapy.
Chemotherapy agent targeting lung and testicular cancers.
Hormone precursor used in synthetic pharmaceutical intermediates.
Natural compound for steroid API production in drugs.
Board of directors of Sai Phytoceuticals Private Limited (Sai Phytoceuticals)
Sai Phytoceuticals Private Limited is the primary company behind Sai Phytoceuticals. The board of Sai Phytoceuticals Private Limited currently have 2 directors; the longest-serving is Anil Gyan Chand Bhansali, appointed in 1995. 1 earlier director has ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Anil Gyan Chand Bhansali DIN 00533601 | Director | 23 Jun 1995 | 31 yrs 3 mo | Sai Phytoceuticals Private Limited |
| Yash Raju Bhansali DIN 00533901 | Director | 23 Jun 1995 | 31 yrs 3 mo | Sai Phytoceuticals Private Limited |
Financials of Sai Phytoceuticals
Figures of Sai Phytoceuticals Private Limited, the primary company behind Sai Phytoceuticals, for FY 2025. Revenue was ₹15.55 Cr (+73% year on year). Net profit was ₹39.9 Lakh (3% margin). EBITDA was ₹1.62 Cr (10% margin). Revenue has grown at a compounded annual rate of +54% over three years and +52% over five years.
- ₹15.55 CrRevenue · FY 2025 · +73% YoY
- ₹39.9 LakhNet profit · 3% margin
- ₹1.62 CrEBITDA · 10% margin
- ₹5.60 CrPaid-up capital
- 34Employees (provident fund records)
- +54%Revenue CAGR, 3 years
- +52%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Sai Phytoceuticals Private Limited are on its company page.
Detailed financial statements for Sai Phytoceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Similar companies to Sai Phytoceuticals
10 companies that operate in the same segment as Sai Phytoceuticals (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Sai Phytoceuticals
Sai Phytoceuticals was founded in 2002.
Sai Phytoceuticals is headquartered in New Delhi, India. It is registered at New Delhi, Delhi, India.
Sai Phytoceuticals has 34 employees.
The primary company behind Sai Phytoceuticals, Sai Phytoceuticals Private Limited, reported revenue of ₹15.55 Cr for FY 2025, up 73% year on year.
Sai Phytoceuticals is a certified company established in 2002, focusing on manufacturing and marketing plant-based products such as oncology APIs, steroid intermediates, and custom synthesized compounds. It operates in the pharmaceutical sector, producing items like Paclitaxel and Cabazitaxel for anti-cancer applications. The company serves both domestic and international markets through B2B channels. Its facilities are located in New Delhi and Bhind, India, ensuring compliance with ISO and GMP standards. Clients include various pharmaceutical entities requiring specialized intermediates.
Sai Phytoceuticals offers PACLITAXEL, CABAZITAXEL, CARFILZOMIB, ETOPOSIDE, and 2 more products and services.
Sai Phytoceuticals operates through Sai Phytoceuticals Private Limited.
The legal entities of Sai Phytoceuticals currently have 2 directors, including Anil Gyan Chand Bhansali, Yash Raju Bhansali.